SHOW / EPISODE

The GLP-1 Economy

11m | Sep 17, 2026

GLP-1 medicines and tirzepatide can produce substantial average weight loss and improve selected cardiometabolic outcomes, but their recurring costs, side effects, access barriers and uncertain long-term savings complicate the case for patients, insurers, employers and public programs. Factolio examines the medical, economic and political consequences.

Read the full discussion and sources:

https://factolio.com/?p=2899

Paused
Audio Player Image
factolio
Loading...